Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus

被引:144
作者
Sieradzki, K [1 ]
Tomasz, A [1 ]
机构
[1] Rockefeller Univ, New York, NY 10021 USA
关键词
D O I
10.1128/JB.185.24.7103-7110.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A series of isogenic methicillin-resistant Staphylococcus aureus isolates recovered from a bacteremic patient were shown to acquire gradually increasing levels of resistance to vancomycin during chemotherapy with the drug (K. Sieradzki, T. Leski, L. Borio, J. Dick, and A. Tomasz, J. Clin. Microbiol. 41:1687-1693, 2003). We compared properties of the earliest (parental) vancomycin-susceptible isolate, JH1 (MIC, 1 mug/ml), to two late (progeny) isolates, JH9 and JH14 (vancomycin MIC, 8 mug/ml). The resistant isolates produced abnormally thick cell walls and poorly separated cells when grown in antibiotic-free medium. Chemical analysis of the resistant isolates showed decreased cross-linkage of the peptidoglycan and drastically reduced levels of PBP4 as determined by the fluorographic assay. Resistant isolates showed reduced rates of cell wall turnover and autolysis. In vitro hydrolysis of resistant cell walls by autolytic extracts prepared from either susceptible or resistant strains was also slow, and this abnormality could be traced to a quantitative (or qualitative) change in the wall teichoic acid component of resistant isolates. Some change in the structure and/or metabolism of teichoic acids appears to be an important component of the mechanism of decreased susceptibility to vancomycin in S. aureus.
引用
收藏
页码:7103 / 7110
页数:8
相关论文
共 25 条
[1]   Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus [J].
Aeschlimann, JR ;
Hershberger, E ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1914-1918
[2]  
Archibald AR., 1972, STAPHYLOCOCCI, P75
[3]   Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates [J].
Boyle-Vavra, S ;
Berke, SK ;
Lee, JC ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :272-277
[4]   A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates [J].
Boyle-Vavra, S ;
Labischinski, H ;
Ebert, CC ;
Ehlert, K ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :280-287
[5]  
*CDC, 1998, MMWR-MORBID MORTAL W, V46, P813
[6]   MICRODETERMINATION OF PHOSPHORUS [J].
CHEN, PS ;
TORIBARA, TY ;
WARNER, H .
ANALYTICAL CHEMISTRY, 1956, 28 (11) :1756-1758
[7]   Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus [J].
Cui, L ;
Ma, XX ;
Sato, K ;
Okuma, K ;
Tenover, FC ;
Mamizuka, EM ;
Gemmell, CG ;
Kim, MN ;
Ploy, MC ;
El Solh, N ;
Ferraz, V ;
Hiramatsu, K .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) :5-14
[8]  
DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248
[9]   Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus [J].
Finan, JE ;
Archer, GL ;
Pucci, MJ ;
Climo, MW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3070-3075
[10]   Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50 [J].
Hanaki, H ;
Labischinski, H ;
Inaba, Y ;
Kondo, N ;
Murakami, H ;
Hiramatsu, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (03) :315-320